This white paper explores:
- Differences between QTc measurements generated by ECG machine algorithms and QTc measurements performed by a centralized core lab
- How the use of ECG machine QTc measurements for screening purposes in clinical oncology trials may impede patient recruitment
- How the use of ECG machine QTc measurements may lead to incorrect dosing decisions
- The limitations of ECG machine measurements in planning ECG collection strategies for oncology trials
More about this white paper:
Many clinical trials of investigational oncologic agents utilize electrocardiogram (ECG) machine measurements of QTc, for inclusion/exclusion and dosing decisions, though their reliability in this setting has not been established. However, this analysis of 270,000 ECGs from multiple oncology studies concluded that as many as 45% of the patients excluded due to prolonged QTc were actually eligible for enrollment when correctly evaluated through centralized ECG measurement.
Learn why reliance on ECG machine QTc measurements during clinical oncology trials may lead to unnecessary exclusion of patients as well as unneeded treatment interruptions.
What you’ll learn:
This paper focuses on how relying on ECG machine QTc measurements during oncology trials can impact dosing decisions and one of the biggest challenges of oncology trials: patient recruitment.